Oral candidiasis

A physical examination is recommended for patients with known medical risk factors for oropharyngeal candidiasis, to establish whether asymptomatic lesions are present. This is especially important for immunocompromised patients, where oropharyngeal candidiasis, if untreated, may become focally invasive or disseminate. In the absence of any lesions, prophylaxis with antifungal agents may still be used to prevent local infection and systemic candidal involvement in patients undergoing radiation and chemotherapeutic cancer treatment.[44]Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003807. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003807.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/17253497?tool=bestpractice.com [45]Worthington HV, Clarkson JE, Khalid T, et al. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2010 Apr 18;(7):CD001972. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001972.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/17443513?tool=bestpractice.com [ ] How do antifungal drugs compare with placebo for preventing oral candidiasis in adults and children undergoing cancer treatment?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2807/fullShow me the answer It may also be used following bone marrow and organ transplants and in immunocompromised states associated with HIV infection.